{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:50:15Z","timestamp":1792180215018,"version":"4.4.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,3,16]],"date-time":"2019-03-16T00:00:00Z","timestamp":1552694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"IBSA Institut Biochimique SA, Lugano, Switzerland"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s12325-019-00921-w","type":"journal-article","created":{"date-parts":[[2019,3,16]],"date-time":"2019-03-16T16:03:43Z","timestamp":1552752223000},"page":"1085-1099","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Efficacy of Chondroitin Sulfate in Patients with Knee Osteoarthritis: A Comprehensive Meta-Analysis Exploring Inconsistencies in Randomized, Placebo-Controlled Trials"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6992-6712","authenticated-orcid":false,"given":"Germain","family":"Honvo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bruy\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Geerinck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Veronese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,16]]},"reference":[{"key":"921_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/bmb\/lds038","volume":"105","author":"A Litwic","year":"2013","unstructured":"Litwic A, Edwards MH, Dennison EM, Cooper C. Epidemiology and burden of osteoarthritis. Br Med Bull. 2013;105:185\u201399.","journal-title":"Br Med Bull"},{"key":"921_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/rheumatology\/41.S1.3","volume":"41","author":"J-Y Reginster","year":"2002","unstructured":"Reginster J-Y. The prevalence and burden of arthritis. Rheumatology (Oxford). 2002;41:3\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"921_CR3","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.semarthrit.2013.07.003","volume":"43","author":"M Hiligsmann","year":"2013","unstructured":"Hiligsmann M, Cooper C, Arden N, et al. Health economics in the field of osteoarthritis: an expert\u2019s consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2013;43:303\u201313.","journal-title":"Semin Arthritis Rheum"},{"key":"921_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.semarthrit.2014.06.005","volume":"44","author":"M Hiligsmann","year":"2014","unstructured":"Hiligsmann M, Cooper C, Guillemin F, et al. A reference case for economic evaluations in osteoarthritis: an expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014;44:271\u201382.","journal-title":"Semin Arthritis Rheum"},{"key":"921_CR5","first-page":"646","volume":"81","author":"AD Woolf","year":"2003","unstructured":"Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ. 2003;81:646\u201356.","journal-title":"Bull World Health Organ"},{"key":"921_CR6","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1136\/ard.2003.011742","volume":"62","author":"KM Jordan","year":"2003","unstructured":"Jordan KM, Arden NK, Doherty M, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the standing committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62:1145\u201355.","journal-title":"Ann Rheum Dis"},{"key":"921_CR7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.joca.2014.01.003","volume":"22","author":"TE McAlindon","year":"2014","unstructured":"McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthr Cartil. 2014;22:363\u201388.","journal-title":"Osteoarthr Cartil."},{"key":"921_CR8","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/acr.21596","volume":"64","author":"MC Hochberg","year":"2012","unstructured":"Hochberg MC, Altman RD, April KT, et al. American college of rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2012;64:465\u201374.","journal-title":"Arthritis Care Res."},{"key":"921_CR9","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.semarthrit.2015.11.010","volume":"45","author":"O Bruy\u00e8re","year":"2016","unstructured":"Bruy\u00e8re O, Cooper C, Pelletier JP, et al. A consensus statement on the european society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-from evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016;45:S3\u201311.","journal-title":"Semin Arthritis Rheum"},{"key":"921_CR10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.semarthrit.2014.05.014","volume":"44","author":"O Bruy\u00e8re","year":"2014","unstructured":"Bruy\u00e8re O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis in europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014;44:253\u201363.","journal-title":"Semin Arthritis Rheum"},{"key":"921_CR11","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.semarthrit.2014.12.003","volume":"44","author":"M Cutolo","year":"2015","unstructured":"Cutolo M, Berenbaum F, Hochberg M, Punzi L, Reginster JY. Commentary on recent therapeutic guidelines for osteoarthritis. Semin Arthritis Rheum. 2015;44:611\u20137.","journal-title":"Semin Arthritis Rheum"},{"key":"921_CR12","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1185\/03007995.2015.1027183","volume":"31","author":"J-Y Reginster","year":"2015","unstructured":"Reginster J-Y, Cooper C, Hochberg M, et al. Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis. Curr Med Res Opin. 2015;31:1041\u20135.","journal-title":"Curr Med Res Opin"},{"key":"921_CR13","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1136\/annrheumdis-2016-210860","volume":"76","author":"JY Reginster","year":"2017","unstructured":"Reginster JY, Dudler J, Blicharski T, Pavelka K. Pharmaceutical-grade chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the chondroitin versus celecoxib versus placebo trial (CONCEPT). Ann Rheum Dis. 2017;76:1537\u201343.","journal-title":"Ann Rheum Dis"},{"key":"921_CR14","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1002\/acr.22376","volume":"66","author":"P Eriksen","year":"2014","unstructured":"Eriksen P, Bartels EM, Altman RD, Bliddal H, Juhl C, Christensen R. Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a meta-analysis of placebo-controlled trials. Arthritis Care Res. 2014;66:1844\u201355.","journal-title":"Arthritis Care Res."},{"key":"921_CR15","unstructured":"Higgins J, Green S (editors). Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011] [Internet]. The Cochrane Collaboration. 2011."},{"key":"921_CR16","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.","journal-title":"PLoS Med."},{"key":"921_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/136245","volume":"2012","author":"C Juhl","year":"2012","unstructured":"Juhl C, Lund H, Roos EM, Zhang W, Christensen R. A hierarchy of patient-reported outcomes for meta-analysis of knee osteoarthritis trials: empirical evidence from a survey of high impact journals. Arthritis. 2012;2012:1\u201317.","journal-title":"Arthritis"},{"key":"921_CR18","first-page":"779","volume":"24","author":"MG Lequesne","year":"1997","unstructured":"Lequesne MG. The algofunctional indices for hip and knee osteoarthritis. J Rheumatol. 1997;24:779\u201381.","journal-title":"J Rheumatol"},{"key":"921_CR19","first-page":"177","volume":"188","author":"R Dersimonian","year":"1986","unstructured":"Dersimonian R, Laird N. Meta-analysis in clinical trials. Stat Med. 1986;188:177\u201388.","journal-title":"Stat Med"},{"key":"921_CR20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","volume":"11","author":"TB Huedo-Medina","year":"2006","unstructured":"Huedo-Medina TB, Sa J, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11:193\u2013206.","journal-title":"Psychol Methods"},{"key":"921_CR21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ Br Med J. 2003;327:557\u201360.","journal-title":"BMJ Br Med J."},{"key":"921_CR22","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/sim.1183","volume":"21","author":"PP Glasziou","year":"2002","unstructured":"Glasziou PP, Sanders SL. Investigating causes of heterogeneity in systematic reviews. Stat Med. 2002;21:1503\u201311.","journal-title":"Stat Med"},{"key":"921_CR23","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"921_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JAC Sterne","year":"2011","unstructured":"Sterne JAC, Sutton AJ, Ioannidis JPA, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:1\u20138.","journal-title":"BMJ"},{"key":"921_CR25","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383\u201394.","journal-title":"J Clin Epidemiol."},{"key":"921_CR26","doi-asserted-by":"crossref","first-page":"438","DOI":"10.5694\/j.1326-5377.2003.tb05627.x","volume":"179","author":"SR Heritier","year":"2003","unstructured":"Heritier SR, Gebski VJ, Keech AC. Inclusion of patients in clinical trial analysis: the intention-to-treat principle. Med J Aust. 2003;179:438\u201340.","journal-title":"Med J Aust"},{"key":"921_CR27","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1177\/1740774515588097","volume":"12","author":"LN Yelland","year":"2015","unstructured":"Yelland LN, Sullivan TR, Voysey M, Lee KJ, Cook JA, Forbes AB. Applying the intention-to-treat principle in practice: guidance on handling randomisation errors. Clin Trials. 2015;12:418\u201323.","journal-title":"Clin Trials."},{"issue":"Suppl A","key":"921_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1063-4584(98)80008-3","volume":"6","author":"P Bourgeois","year":"1998","unstructured":"Bourgeois P, Chales G, Dehais J, Delcambre B, Kuntz JL, Rozenberg S. Efficacy and tolerability of chondroitin sulfate 1200\u00a0mg\/day vs chondroitin sulfate 3 \u00d7 400\u00a0mg\/day vs placebo. Osteoarthr Cartil. 1998;6(Suppl A):25\u201330.","journal-title":"Osteoarthr Cartil."},{"issue":"Suppl A","key":"921_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1063-4584(98)80009-5","volume":"6","author":"L Bucsi","year":"1998","unstructured":"Bucsi L, Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthr Cartil. 1998;6(Suppl A):31\u20136.","journal-title":"Osteoarthr Cartil."},{"key":"921_CR30","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa052771","volume":"354","author":"DO Clegg","year":"2006","unstructured":"Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354:795\u2013808.","journal-title":"N Engl J Med"},{"key":"921_CR31","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1136\/annrheumdis-2013-203954","volume":"74","author":"M Fransen","year":"2015","unstructured":"Fransen M, Agaliotis M, Nairn L, et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis. 2015;74:851\u20138.","journal-title":"Ann Rheum Dis"},{"key":"921_CR32","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1002\/art.30574","volume":"63","author":"C Gabay","year":"2011","unstructured":"Gabay C, Medinger-Sadowski C, Gascon D, Kolo F, Finckh A. Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single center. Arthritis Rheum. 2011;63:3383\u201391.","journal-title":"Arthritis Rheum"},{"key":"921_CR33","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/art.24255","volume":"60","author":"A Kahan","year":"2009","unstructured":"Kahan A, Uebelhart D, De Vathaire F, Delmas PD, Reginster J-Y. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2009;60:524\u201333.","journal-title":"Arthritis Rheum"},{"key":"921_CR34","first-page":"466","volume":"59","author":"B Mazieres","year":"1992","unstructured":"Mazieres B, Loyau G, Menkes C, et al. Chondroitin sulfate for the treatment of coxarthrosis and gonarthrosis: a prospective, multicenter, placebo-controlled, double-blind trial with five months follow-up. Rev Rhum Mal Osteoartic. 1992;59:466\u201372.","journal-title":"Rev Rhum Mal Osteoartic."},{"key":"921_CR35","first-page":"173","volume":"28","author":"B Mazieres","year":"2001","unstructured":"Mazieres B, Combe B, Van Phan A, Tondut J, Grynfeltt M. Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. J Rheumatol. 2001;28:173\u201381.","journal-title":"J Rheumatol"},{"key":"921_CR36","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/ard.2006.059899","volume":"66","author":"B Mazieres","year":"2007","unstructured":"Mazieres B, Hucher M, Zaim M, Garnero P. Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2007;66:639\u201345.","journal-title":"Ann Rheum Dis"},{"key":"921_CR37","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/j.joca.2010.01.018","volume":"18","author":"I M\u00f6ller","year":"2010","unstructured":"M\u00f6ller I, P\u00e9rez M, Monfort J, et al. Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double-blind, placebo-controlled study. Osteoarthr Cartil. 2010;18:S32\u201340.","journal-title":"Osteoarthr Cartil."},{"key":"921_CR38","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.medcli.2016.12.036","volume":"148","author":"J Monfort","year":"2017","unstructured":"Monfort J, Pujol J, Contreras-Rodriguez O, et al. Effects of chondroitin sulfate on brain response to painful stimulation in knee osteoarthritis patients: a randomized, double-blind, placebo-controlled functional magnetic resonance imaging study. Med Clin (Barc). 2017;148:539\u201347.","journal-title":"Med Clin (Barc)."},{"key":"921_CR39","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s10067-012-2022-4","volume":"31","author":"JJ Railhac","year":"2012","unstructured":"Railhac JJ, Zaim M, Saurel AS, Vial J, Fournie B. Effect of 12\u00a0months treatment with chondroitin sulfate on cartilage volume in knee osteoarthritis patients: a randomized, double-blind, placebo-controlled pilot study using MRI. Clin Rheumatol. 2012;31:1347\u201357.","journal-title":"Clin Rheumatol"},{"issue":"Suppl A","key":"921_CR40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1063-4584(98)80011-3","volume":"6","author":"D Uebelhart","year":"1998","unstructured":"Uebelhart D, Thonar EJ, Delmas PD, Chantraine A, Vignon E. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthr Cartil. 1998;6(Suppl A):39\u201346.","journal-title":"Osteoarthr Cartil."},{"key":"921_CR41","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.joca.2004.01.004","volume":"12","author":"D Uebelhart","year":"2004","unstructured":"Uebelhart D, Malaise M, Marcolongo R, et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthr Cartil. 2004;12:269\u201376.","journal-title":"Osteoarthr Cartil."},{"key":"921_CR42","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1136\/ard.2010.140848","volume":"70","author":"LM Wildi","year":"2011","unstructured":"Wildi LM, Raynauld J-P, Martel-Pelletier J, et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6\u00a0months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis. 2011;70:982\u20139.","journal-title":"Ann Rheum Dis"},{"key":"921_CR43","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.joca.2012.09.017","volume":"21","author":"B Zegels","year":"2013","unstructured":"Zegels B, Crozes P, Uebelhart D, Bruy\u00e8re O, Reginster JY. Equivalence of a single dose (1200\u00a0mg) compared to a three-time a day dose (400\u00a0mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis: results of a randomized double blind placebo controlled study. Osteoarthr Cartil. 2013;21:22\u20137.","journal-title":"Osteoarthr Cartil."},{"key":"921_CR44","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.jclinepi.2005.01.006","volume":"58","author":"N Terrin","year":"2005","unstructured":"Terrin N, Schmid CH, Lau J. In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias. J Clin Epidemiol. 2005;58:894\u2013901.","journal-title":"J Clin Epidemiol"},{"key":"921_CR45","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 7. Rating the quality of evidence\u2014inconsistency. J Clin Epidemiol. 2011;64:1294\u2013302.","journal-title":"J Clin Epidemiol."},{"key":"921_CR46","doi-asserted-by":"crossref","unstructured":"Singh JA, Noorbaloochi S, Macdonald R, Maxwell LJ. Chondroitin for osteoarthritis. Cochrane Database Syst Rev. 2015.","DOI":"10.1002\/14651858.CD005614.pub2"},{"key":"921_CR47","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1001\/jama.283.11.1469","volume":"283","author":"TE McAlindon","year":"2000","unstructured":"McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis. JAMA. 2000;283:1469.","journal-title":"JAMA"},{"key":"921_CR48","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1001\/archinte.163.13.1514","volume":"163","author":"F Richy","year":"2003","unstructured":"Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y, Reginster J-Y. Structural and symptomatic efficacy of glucsamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med. 2003;163:1514\u201322.","journal-title":"Arch Intern Med"},{"key":"921_CR49","first-page":"205","volume":"27","author":"B Leeb","year":"2000","unstructured":"Leeb B, Schweitzer H, Montag K, Smolen J. A meta-analysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol. 2000;27:205\u201311.","journal-title":"J Rheumatol"},{"key":"921_CR50","doi-asserted-by":"publisher","first-page":"580","DOI":"10.7326\/0003-4819-146-8-200704170-00009","volume":"146","author":"S Reichenbach","year":"2007","unstructured":"Reichenbach S, Sterchi R, Scherer M, et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med. 2007;146:580\u201390.","journal-title":"Ann Intern Med"},{"key":"921_CR51","doi-asserted-by":"publisher","first-page":"c4675","DOI":"10.1136\/bmj.c4675","volume":"341","author":"S Wandel","year":"2010","unstructured":"Wandel S, Juni P, Tendal B, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ. 2010;341:c4675.","journal-title":"BMJ"},{"key":"921_CR52","doi-asserted-by":"crossref","unstructured":"Towheed T, Maxwell L, Anastassiades T, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2009.","DOI":"10.1002\/14651858.CD002946.pub2"},{"key":"921_CR53","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1211\/jpp.61.10.0002","volume":"61","author":"N Volpi","year":"2009","unstructured":"Volpi N. Quality of different chondroitin sulfate preparations in relation to their therapeutic activity. J Pharm Pharmacol. 2009;61:1271\u201380.","journal-title":"J Pharm Pharmacol"},{"key":"921_CR54","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40520-017-0861-1","volume":"30","author":"O Bruy\u00e8re","year":"2018","unstructured":"Bruy\u00e8re O, Cooper C, Al-Daghri NM, Dennison EM, Rizzoli R, Reginster JY. Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clin Exp Res. 2018;30:111\u20137.","journal-title":"Aging Clin Exp Res"},{"key":"921_CR55","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/art.20867","volume":"52","author":"BA Michel","year":"2005","unstructured":"Michel BA, Stucki G, Frey D, et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum. 2005;52:779\u201386.","journal-title":"Arthritis Rheum"},{"key":"921_CR56","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.joca.2010.02.016","volume":"18","author":"MC Hochberg","year":"2010","unstructured":"Hochberg MC. Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration. Osteoarthr Cartil. 2010;18:S28\u201331.","journal-title":"Osteoarthr Cartil."},{"key":"921_CR57","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jclinepi.2010.12.006","volume":"64","author":"JC Sinclair","year":"2011","unstructured":"Sinclair JC, Haynes RB. Selecting participants that raise a clinical trial\u2019s population attributable fraction can increase the treatment effect within the trial and reduce the required sample size. J Clin Epidemiol. 2011;64:893\u2013902.","journal-title":"J Clin Epidemiol"},{"key":"921_CR58","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1136\/bmj.308.6921.72","volume":"308","author":"DG Smith","year":"1994","unstructured":"Smith DG, Egger M. Who benefits from medical interventions? treating low risk patients can be a high risk strategy. Br Med J. 1994;308:72\u20134.","journal-title":"Br Med J"},{"key":"921_CR59","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.joca.2007.02.006","volume":"15","author":"J Avouac","year":"2007","unstructured":"Avouac J, Gossec L, Dougados M. Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials. Osteoarthr Cartil. 2007;15:957\u201365.","journal-title":"Osteoarthr Cartil."},{"key":"921_CR60","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.semarthrit.2016.02.010","volume":"46","author":"M Johansen","year":"2016","unstructured":"Johansen M, Bahrt H, Altman RD, et al. Exploring reasons for the observed inconsistent trial reports on intra-articular injections with hyaluronic acid in the treatment of osteoarthritis: meta-regression analyses of randomized trials. Semin Arthritis Rheum. 2016;46:34\u201348.","journal-title":"Semin Arthritis Rheum"},{"key":"921_CR61","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.joca.2010.01.013","volume":"18","author":"W Zhang","year":"2010","unstructured":"Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartil. 2010;18:476\u201399.","journal-title":"Osteoarthr Cartil."},{"key":"921_CR62","unstructured":"The European Medicines Agency. Guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis. European medicines agency. London, 20 January 2010; 2010."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00921-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-00921-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00921-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T18:27:36Z","timestamp":1663093656000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-00921-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,16]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["921"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-00921-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,16]]},"assertion":[{"value":"30 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}